Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus

Joy Cuthberston; Steven Patterson; Finbarr O'Harte; Patrick  Bell

doi:10.1016/j.metabol.2010.01.001

Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus

Joy Cuthberston, Steven Patterson, Finbarr O'Harte, Patrick Bell

Biological and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that lowers blood glucose after meals in type 2 diabetes mellitus. The therapeutic potential of GLP-1 in diabetes is limited by rapid inactivation by the enzyme dipeptidylpeptidase-4 (DPP-4). Metformin has been reported to inhibit DPP-4. Here we investigated the acute effects of metformin and GLP-1 alone or in combination on plasma DPP-4 activity, active GLP-1 concentrations, and glucose lowering in type 2 diabetes mellitus.

Original language	English
Pages (from-to)	52-56
Number of pages	5
Journal	Metabolism
Volume	60
Issue number	1
DOIs	https://doi.org/10.1016/j.metabol.2010.01.001
Publication status	Published - Jan 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Documents and Links

10.1016/j.metabol.2010.01.001

Cite this

@article{2450e044474447c1908b46a65fa67a64,

title = "Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus",

abstract = "Glucagon-like peptide-1 (GLP-1) is an incretin hormone that lowers blood glucose after meals in type 2 diabetes mellitus. The therapeutic potential of GLP-1 in diabetes is limited by rapid inactivation by the enzyme dipeptidylpeptidase-4 (DPP-4). Metformin has been reported to inhibit DPP-4. Here we investigated the acute effects of metformin and GLP-1 alone or in combination on plasma DPP-4 activity, active GLP-1 concentrations, and glucose lowering in type 2 diabetes mellitus. ",

author = "Joy Cuthberston and Steven Patterson and Finbarr O'Harte and Patrick Bell",

year = "2011",

month = jan,

doi = "10.1016/j.metabol.2010.01.001",

language = "English",

volume = "60",

pages = "52--56",

journal = "Metabolism ",

issn = "0026-0495",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus

AU - Cuthberston, Joy

AU - Patterson, Steven

AU - O'Harte, Finbarr

AU - Bell, Patrick

PY - 2011/1

Y1 - 2011/1

N2 - Glucagon-like peptide-1 (GLP-1) is an incretin hormone that lowers blood glucose after meals in type 2 diabetes mellitus. The therapeutic potential of GLP-1 in diabetes is limited by rapid inactivation by the enzyme dipeptidylpeptidase-4 (DPP-4). Metformin has been reported to inhibit DPP-4. Here we investigated the acute effects of metformin and GLP-1 alone or in combination on plasma DPP-4 activity, active GLP-1 concentrations, and glucose lowering in type 2 diabetes mellitus.

AB - Glucagon-like peptide-1 (GLP-1) is an incretin hormone that lowers blood glucose after meals in type 2 diabetes mellitus. The therapeutic potential of GLP-1 in diabetes is limited by rapid inactivation by the enzyme dipeptidylpeptidase-4 (DPP-4). Metformin has been reported to inhibit DPP-4. Here we investigated the acute effects of metformin and GLP-1 alone or in combination on plasma DPP-4 activity, active GLP-1 concentrations, and glucose lowering in type 2 diabetes mellitus.

U2 - 10.1016/j.metabol.2010.01.001

DO - 10.1016/j.metabol.2010.01.001

M3 - Article

SN - 0026-0495

VL - 60

SP - 52

EP - 56

JO - Metabolism

JF - Metabolism

IS - 1

ER -

Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus

Abstract

UN SDGs

Documents and Links

Fingerprint

Cite this